• Visit the USI website
  • Go back to the homepage

Institute for Research in Biomedicine
Istituto di Ricerca in Biomedicina

Via Vincenzo Vela 6 - CH-6500 Bellinzona
Tel. +41 91 820 0300 - Fax +41 91 820 0302 - info [at] irb [dot] usi [dot] ch

Laurent Perez, PhD

Scientist, Responsible for the protein production Facility

Via Vela, 6
6500 Bellinzona, Switzerland

Bio

Laurent Perez earned a joined PhD degree from both the European Molecular Biology Laboratory (EMBL) and Heidelberg Universität (Germany). He obtained an EMBL/EMBO fellowship to investigate the molecular mechanism of Cyclin Dependent Kinases (CDKs) activations during cell cycle progression. He performed Structural analysis of microtubule associated proteins and explored post-translational modification of poxvirus-encoded proteins during his postdoctoral at EMBL and the Centre for Genomic Regulation (Spain). After this academic training, he joined the pharmaceutical industry (United Kingdom and Switzerland) as an independent researcher to study host-pathogen interaction and design virus like particle vaccines. In 2011, he returned to academic research as head of the Gene Expression and Protein Production Platform at the Institute for Research in Biomedicine (Bellinzona, Switzerland). Besides managing the platform, Laurent is exploring the molecular mechanisms of Human Cytomegalovirus (HCMV) viral entry and performing vaccine design against HCMV and Paramyxoviruses. Laurent’s focus is to use targeted and rational approaches for vaccine design by combining protein engineering and in vivo evaluation of viral glycoproteins.     

Progetti
Deciphering the class and specificity of the T cell response to C. albicans
Pubblicazioni
An Unbiased Screen for Human Cytomegalovirus Identifies Neuropilin-2 as a Central Viral Receptor
N. Martinez-Martin, J. Marcandalli, C. S. Huang, C. P. Arthur, M. Perotti, M. Foglierini, H. Ho, A. M. Dosey, S. Shriver, J. Payandeh, A. Leitner, A. Lanzavecchia, L. Perez, C. Ciferri
in Cell (2018)
* L. Perez and C. Ciferri contributed equally; N M-M, LP and CC are co-corresponding authors
Human cytomegalovirus (HCMV)-specific T-cell but not neutralizing or ELISA IgG antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients
D. Lilleri, P. Zelini, C. Fornara, F. Zavaglio, T. Rampino, L. Perez, E. Gabanti, G. Gerna
in J Med Virol (2018)
False human cytomegalovirus IgG-positivity at prenatal screening
M. Furione, A. Sarasini, A. Arossa, C. Fornara, D. Lilleri, L. Perez, M. Parea, M. Zavattoni, A. Spinillo, P. Marone, F. Baldanti
in J Clin Virol (2018) vol. 104 pp34-38
A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein
J. Tan, B. K. Sack, D. Oyen, I. Zenklusen, L. Piccoli, S. Barbieri, M. Foglierini, C. S. Fregni, J. Marcandalli, S. Jongo, S. Abdulla, L. Perez, G. Corradin, L. Varani, F. Sallusto, B. K. L. Sim, S. L. Hoffman, S. H. I. Kappe, C. Daubenberger, I. A. Wilson, A. Lanzavecchia
in Nat Med (2018) vol. 24 pp401-407
Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
D. Genini, L. Brambilla, E. Laurini, J. Merulla, G. Civenni, S. Pandit, R. D'Antuono, L. Perez, D. E. Levy, S. Pricl, G. M. Carbone, C. V. Catapano
in Proc Natl Acad Sci U S A (2017) vol. 114 ppE4924-E4933
The C-terminal domain of TPX2 is made of alpha-helical tandem repeats
L. Sanchez-Pulido, L. Perez, S. Kuhn, I. Vernos, M. A. Andrade-Navarro
in BMC Struct Biol (2016) vol. 16 pp17
Perez L. and Sanchez-Pulido L. contributed equally to this work.
Antibody-guided vaccine design: identification of protective epitopes
A. Lanzavecchia, A. Fruhwirth, L. Perez, D. Corti
in Curr Opin Immunol (2016) vol. 41 pp62-67
Platelet-derived growth factor-alpha receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer
A. Kabanova, J. Marcandalli, T. Zhou, S. Bianchi, U. Baxa, Y. Tsybovsky, D. Lilleri, C. Silacci-Fregni, M. Foglierini, B. M. Fernandez-Rodriguez, A. Druz, B. Zhang, R. Geiger, M. Pagani, F. Sallusto, P. D. Kwong, D. Corti, A. Lanzavecchia, L. Perez
in Nat Microbiol (2016) vol. 1 pp16082
Anna Kabanova, Jessica Marcandalli, Tongqing Zhou equally contributed to this work; Antonio Lanzavecchia1and Laurent Perez jointly supervised this work.
Monoclonal antibodies to different components of the human cytomegalovirus (HCMV) pentamer gH/gL/pUL128L and trimer gH/gL/gO as well as antibodies elicited during primary HCMV infection prevent epithelial cell syncytium formation
G. Gerna, E. Percivalle, L. Perez, A. Lanzavecchia, D. Lilleri
in J Virol (2016) vol. 90 pp6216-23
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
D. Corti, J. Misasi, S. Mulangu, D. A. Stanley, M. Kanekiyo, S. Wollen, A. Ploquin, N. A. Doria-Rose, R. P. Staupe, M. Bailey, W. Shi, M. Choe, H. Marcus, E. A. Thompson, A. Cagigi, C. Silacci, B. Fernandez-Rodriguez, L. Perez, F. Sallusto, F. Vanzetta, G. Agatic, E. Cameroni, N. Kisalu, I. Gordon, J. E. Ledgerwood, J. R. Mascola, B. S. Graham, J. J. Muyembe-Tamfun, J. C. Trefry, A. Lanzavecchia, N. J. Sullivan
in Science (2016) vol. 351 pp1339-42
Davide Corti and John Misasi equally contributed to this work; John C. Trefry, Antonio Lanzavecchia, and Nancy J. Sullivan equally contributed to this work.
Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
L. Brambilla, D. Genini, E. Laurini, J. Merulla, L. Perez, M. Fermeglia, G. M. Carbone, S. Pricl, C. V. Catapano
in Mol Oncol (2015) vol. 9 pp1194-206
Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies
A. Kabanova, L. Perez, D. Lilleri, J. Marcandalli, G. Agatic, S. Becattini, S. Preite, D. Fuschillo, E. Percivalle, F. Sallusto, G. Gerna, D. Corti, A. Lanzavecchia
in Proc Natl Acad Sci U S A (2014) vol. 111 pp17965-70
A.K. and L.P. contributed equally to this work.
Cross-neutralization of four paramyxoviruses by a human monoclonal antibody
D. Corti, S. Bianchi, F. Vanzetta, A. Minola, L. Perez, G. Agatic, B. Guarino, C. Silacci, J. Marcandalli, B. J. Marsland, A. Piralla, E. Percivalle, F. Sallusto, F. Baldanti, A. Lanzavecchia
in Nature (2013) vol. 501 pp439-43
Direct bacterial killing in vitro by recombinant Nod2 is compromised by Crohn's disease-associated mutations
L. H. Perez, M. Butler, T. Creasey, J. Dzink-Fox, J. Gounarides, S. Petit, A. Ropenga, N. Ryder, K. Smith, P. Smith, S. J. Parkinson
in PLoS One (2010) vol. 5 ppe10915
The plant TPX2 protein regulates prospindle assembly before nuclear envelope breakdown
J. W. Vos, L. Pieuchot, J. L. Evrard, N. Janski, M. Bergdoll, D. de Ronde, L. H. Perez, T. Sardon, I. Vernos, A. C. Schmit
in Plant Cell (2008) vol. 20 pp2783-97
Negative regulation of cell-cycle progression by RINGO/Speedy E
A. Dinarina, E. J. Ruiz, A. O'Loghlen, S. Mouron, L. Perez, A. R. Nebreda
in Biochem J (2008) vol. 410 pp535-42
Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its self-association
S. Palacios, L. H. Perez, S. Welsch, S. Schleich, K. Chmielarska, F. Melchior, J. K. Locker
in Mol Biol Cell (2005) vol. 16 pp2822-35
Characterization of a new family of cyclin-dependent kinase activators
A. Dinarina, L. H. Perez, A. Davila, M. Schwab, T. Hunt, A. R. Nebreda
in Biochem J (2005) vol. 386 pp349-55
Xkid chromokinesin is required for the meiosis I to meiosis II transition in Xenopus laevis oocytes
L. H. Perez, C. Antonio, S. Flament, I. Vernos, A. R. Nebreda
in Nat Cell Biol (2002) vol. 4 pp737-42
Differential regulation of Cdc2 and Cdk2 by RINGO and cyclins
A. Karaiskou, L. H. Perez, I. Ferby, R. Ozon, C. Jessus, A. R. Nebreda
in J Biol Chem (2001) vol. 276 pp36028-34